newsfilter
← Latest News
Business Wire·

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021

Results demonstrate changes in gut microbiome structure following administration of Blautix in both IBS-C and IBS-D patients 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LB